Get the Stockscreener App
4.48
3.03%
-0.14
After Hours:
4.48
Maxcyte Inc stock is traded at $4.48, with a volume of 323.71K.
It is down -3.03% in the last 24 hours and up +4.19% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$4.62
Open:
$4.67
24h Volume:
323.71K
Relative Volume:
0.52
Market Cap:
$472.56M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-13.18
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
-2.40%
1M Performance:
+4.19%
6M Performance:
+0.67%
1Y Performance:
-9.31%
1-Day Range:
$4.445
$4.67
1-Week Range:
$4.26
$4.74
52-Week Range:
$3.165
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
4.48 | 472.56M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte® acquires SeQure Dx to broaden cell engineering offerings with on-target and off-target editing assessments - News-Medical.Net
BlackRock, Inc. Reduces Stake in MaxCyte Inc: An In-Depth Analys - GuruFocus.com
MaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by Gagnon Securities LLC - MarketBeat
MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks
MaxCyte Expands Stock Capital with New Common Stock Issuance - TipRanks
MaxCyte Announces Executive Stock Transaction - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
ConnectOne Bancorp (CNOB) Issues Press Release on Acquisition of SeQure Dx by MaxCyte - Defense World
MaxCyte, Inc. Acquires SeQure DX Inc. to Enhance Cell Engineering Offerings - Defense World
MaxCyte director exercises options, sells shares - Investing.com
MaxCyte director exercises options, sells shares By Investing.com - Investing.com UK
MaxCyte Acquires SeQure Dx - FinSMEs
MaxCyte Buys SeQure Dx for Up to $7M - USA Herald
MaxCyte announces acquisition of SeQure Dx - ShareCast
Market news - Research the market
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) -January 30, 2025 at 10:37 am EST - Marketscreener.com
Cell Engineering Biz MaxCyte Buys Gene Firm For Up To $7M - Law360
MaxCyte buys gene therapy analytics firm SeQure Dx -January 30, 2025 at 08:56 am EST - Marketscreener.com
MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion - TipRanks
Cell Engineering Group MaxCyte Buys US-based SeQure Dx -January 30, 2025 at 05:05 am EST - Marketscreener.com
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx -January 30, 2025 at 04:25 am EST - Marketscreener.com
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - The Manila Times
MaxCyte Expands Cell Engineering Capabilities with Acquisition of SeQure Dx - TipRanks
MaxCyte's Strategic Move: $7M Deal Transforms Gene Therapy Safety Testing Landscape - StockTitan
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame - Yahoo Finance
Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65? - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
JPMorgan Chase & Co. Decreases Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Stock Price Down 5.8%Here's What Happened - MarketBeat
How to interpret MaxCyte Inc (MXCT)’s stock chart patterns - US Post News
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
MaxCyte Sees Increase in BlackRock Holdings - TipRanks
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why - Yahoo Finance
BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks
MaxCyte (NASDAQ: MXCT) Announces Preliminary Financial Results for Q4 and FY 2024ROCKVILLE, MD, January 13, 2025 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent cell-engineering company specializing in platform technologies for adv - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLC - Defense World
Barclays PLC Has $645,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy - MSN
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing? - Yahoo Finance
Maxcyte general counsel sells shares worth $20,271 By Investing.com - Investing.com Nigeria
MaxCyte estimates higher Q4 core revenue from last year - MSN
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):